AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy of mFOLFOXIRI plus cetuximab and avelumab
as first line treatment of patients with initially unresectable and previously untreated RAS
wild-type metastatic colorectal cancer (mCRC), in terms of Progression-free Survival.